MSLN and mesothelioma: Additionally, we describe the development of a novel ADC targeting mesothelin (MSLN), a cell surface protein that is over-expressed by a number of tumor types including mesothelioma, lung, pancreatic, ovarian, colorectal, cholangial, gastric and endometrial carcinomas [7, 8].